Bayer Healthcare is paying Regeneron Pharmaceuticals Inc. up to $320 million - including $75 million up front - in a deal centered on VEFG Trap for diseases of the eye, and expects to start a Phase III trial in the first half of next year comparing the drug to Lucentis against age-related macular degeneration. (BioWorld Today) Read More
